- Home
- GNSS vs CNTB Comparison
GNSS vs CNTB Comparison
Compare GNSS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- CNTB
- Stock Information
- Founded
- GNSS 1992
- CNTB 2012
- Country
- GNSS United States
- CNTB United States
- Employees
- GNSS N/A
- CNTB N/A
- Industry
- GNSS Consumer Electronics/Appliances
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- CNTB Health Care
- Exchange
- GNSS Nasdaq
- CNTB Nasdaq
- Market Cap
- GNSS 169.5M
- CNTB 68.5M
- IPO Year
- GNSS N/A
- CNTB 2021
- Fundamental
- Price
- GNSS $3.75
- CNTB $1.17
- Analyst Decision
- GNSS Strong Buy
- CNTB Strong Buy
- Analyst Count
- GNSS 3
- CNTB 1
- Target Price
- GNSS $5.08
- CNTB $8.00
- AVG Volume (30 Days)
- GNSS 106.7K
- CNTB 24.6K
- Earning Date
- GNSS 12-05-2024
- CNTB 09-05-2024
- Dividend Yield
- GNSS N/A
- CNTB N/A
- EPS Growth
- GNSS N/A
- CNTB N/A
- EPS
- GNSS N/A
- CNTB N/A
- Revenue
- GNSS $27,968,000.00
- CNTB $24,116,000.00
- Revenue This Year
- GNSS N/A
- CNTB N/A
- Revenue Next Year
- GNSS $138.10
- CNTB $63.90
- P/E Ratio
- GNSS N/A
- CNTB N/A
- Revenue Growth
- GNSS N/A
- CNTB N/A
- 52 Week Low
- GNSS $1.51
- CNTB $0.68
- 52 Week High
- GNSS $4.04
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- GNSS 60.29
- CNTB 44.02
- Support Level
- GNSS $3.67
- CNTB $1.18
- Resistance Level
- GNSS $3.94
- CNTB $1.26
- Average True Range (ATR)
- GNSS 0.14
- CNTB 0.07
- MACD
- GNSS -0.02
- CNTB -0.01
- Stochastic Oscillator
- GNSS 77.78
- CNTB 13.59
About GNSS Genasys Inc.
Genasys Inc is a provider of critical communications solutions designed to help keep people safe. The company is engaged in the design, development, and commercialization of directed and multidirectional sound technologies, voice broadcast products and location-based mass messaging solutions for emergency warning and workforce management. Its operating segment includes Hardware and Software. The company generates maximum revenue from the Hardware segment. Geographically, it derives a majority of revenue from the Americas region and also has its presence in the Asia Pacific and Europe, Middle East and Africa.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.